Results for "Zoetis"

Financial analysts at Morningstar evaluate Zoetis Inc.’s current share price relative to its estimated fair value, offering insights for potential investors.

Stifel has reduced its stock price targets for both Zoetis and Viking Holdings. The adjustments were made due to concerns over weakness in a key franchise for Zoetis and water level issues impacting Viking Holdings.

Zoetis shares increased after the FDA granted Emergency Use Authorization (EUA) for its Simparica TRIO drug to treat New World screwworm.

Several companies, including Gran Tierra Energy, goeasy, and Finning International, have released highlights from their second-quarter earnings calls. These reports provide insights into their financial performance and operational updates for the recent quarter.

Investor Michael Burry has reportedly doubled his stake in Zoetis stock, signaling a strong 'bull case' for the animal health company. This move highlights confidence in Zoetis's market position and future growth prospects.

Zoetis (ZTS) experienced a decline in its stock value, attributed to a weak market response to its recently introduced 'Great Ideas' initiatives.

Wedgewood Partners made significant changes to its investment portfolio in the second quarter, adding Hermès while exiting positions in Tractor Supply and Zoetis.

Zoetis (ZTS) shares experienced a significant 22% drop in a single day, raising concerns among Wall Street investors.

Jim Cramer shared his apprehension regarding Zoetis's stock performance and suggested a rival company as his preferred pick.

Investors in securities fraud lawsuits against AeroVironment, Inc. (NASDAQ: AVAV) and Zoetis Inc. (NYSE: ZTS) are encouraged to contact Kaplan Fox before the lead plaintiff deadline on July 27, 2026.

A market digest provides updates and analysis on the performance and news related to companies such as Lowe's (LOW), Aptiv (APTV), and Zoetis (ZTS).

Wall Street analysts have identified Zoetis, Coupang, and Flutter Entertainment as some of the best stocks to buy on the New York Stock Exchange. These companies are highlighted for their strong performance and investment potential.

Shares of Zoetis experienced a significant drop in value today, prompting analysis into the reasons behind the decline.

Citi has designated Zoetis as its top stock pick with a 'Buy' rating, highlighting the potential of the pet economy as a significant investment trend for 2026.

Zoetis has published the transcript of its third-quarter 2024 earnings call, offering insights into its financial results.

Bristol Gate Capital Partners has sold its stake in Zoetis (ZTS), citing deteriorating dividend growth as the reason for the divestment.

Zacks.com featured highlights include Ross Stores, Globe Life, Banco Bilbao, Zoetis and TE Connectivity  The Globe and Mail

Barclays has reiterated its 'Hold' rating for Zoetis Inc. (ZTS), indicating a neutral outlook on the stock.

Zoetis has received emergency authorization for its product Simparica Trio, raising questions about its potential to support the company's slowing U.S. business.

Bread Financial stock reached a 52-week high, while O-I Glass, Zoetis, and RBA stocks all hit 52-week lows. These movements reflect significant price fluctuations for these individual companies.

Wall Street analysts are presenting varied opinions on Zoetis stock, with some holding bullish views and others expressing bearish sentiments regarding the company's market prospects.

Zoetis Inc. has released its earnings summary for the second quarter of 2026, outlining its financial results and operational performance in the animal health sector.

Zoetis (ZTS) is experiencing a slowdown in growth, attributed to a decrease in demand within the pet care market.

Despite temporary concerns, the current market conditions for Zoetis (ZTS) stock are being viewed as a potential entry point for investors. This analysis suggests that short-term issues may not reflect the long-term value of the company.

Zoetis, a global animal health company, has announced its intention to acquire VitalRADS, a company specializing in veterinary imaging services.

Zoetis (ZTS) and American Express (AXP) have been highlighted as attractive investment opportunities. Analysts are pointing to factors that make these companies appealing bets for investors.

An article examines the stock performance of Zoetis, comparing its trajectory and metrics against other companies within the healthcare sector.

Zoetis Inc., Intuit Inc., and Charter Communications Inc. have been identified as some of the most oversold S&P 500 stocks in 2026. This assessment highlights their current market position relative to their recent performance.

This article provides an overview of analyst estimates and ratings concerning Zoetis stock, reflecting market expectations for the animal health company.

Zoetis Inc. announced an expansion of the capabilities of its Vetscan OptiCell platform. This enhancement aims to improve diagnostic tools for veterinary professionals.

A summary of the leading Wall Street analyst research calls for Wednesday, covering various companies including Align Technology, American Tower, Autodesk, and others.

Yahoo has published the transcript of Zoetis's (ZTS) second-quarter 2025 earnings call.

An article explores the reasons why Zoetis (ZTS) is considered a potential investment opportunity.

Phibro Animal Health has raised its financial guidance during a BofA Conference, citing progress in Zoetis MFA integration.

Zoetis (ZTS) stock has declined after reporting disappointing Q3 results and experiencing weakness in demand for its Librela product.

Zoetis has released its earnings report, revealing a divided business landscape, with analysts questioning if its product pipeline can restore growth for the company.

A financial analysis questions why Zoetis (ZTS), a leading company in its sector, experienced a sale, despite its strong market position.

An article examines why Zoetis, which previously appeared to be a strong performer, may have encountered difficulties.

Zoetis expects a softer demand in the pet health sector and is adapting its commercial strategy to navigate these anticipated headwinds.

An Oregon veterinarian is suing an AI company, Zoetis, alleging that a misdiagnosis of a cancer tumor in an 11-year-old dog led to its death. The lawsuit claims the company altered its report and admitted to similar misidentifications.

The proposed acquisition deal between animal health companies Zoetis and Neogen is drawing scrutiny and antitrust concerns from authorities in Australia.

This article offers an evaluation of Zoetis Inc. (ZTS) stock, examining its performance and prospects for investors.

Jim Cramer provided his insights on various stocks, highlighting Cisco Systems as a top Dow performer and discussing companies like Energy Transfer, Signet Jewelers, Netflix, Kraft Heinz, Yum, McDonald's, and Kimberly-Clark. He also outlined his top 10 things to watch in the stock market for Friday.

Zoetis Inc. (ZTS) has been downgraded by analysts following a steep market selloff. The downgrade reflects concerns about the company's performance in the current economic climate.

Wall Street analysts have identified Zoetis (ZTS) and LPL Financial Holdings (LPLA) as top wide moat stocks to buy. These recommendations are based on the companies' strong competitive advantages and market positions.

Jim Cramer described Zoetis as a 'quality company' despite its recent stock declines.

Zoetis, an animal health company, projects 2%-5% revenue growth for 2026, anticipating a softening in demand for companion animals in the U.S.

These articles provide an analysis of whether Zoetis Inc. (ZTS) and Applied Materials, Inc. (AMAT) are good stocks to buy now. They likely delve into their financial performance and market prospects to guide potential investors.

This article provides a transcript of the Q3 2025 earnings call for Zoetis (ZTS), detailing the company's financial performance and outlook.

This article explores the long-term growth potential of Zoetis (ZTS), inviting readers to consider the company's future prospects as an investment.

Jensen Quality Growth Equity has divested its stake in Zoetis (ZTS), indicating a change in its investment portfolio.

An analysis questions whether Zoetis stock (ZTS) is underperforming compared to the broader healthcare sector, examining its market position and financial metrics.

Discussions from the Bank of America conference highlight Bread Financial's credit and loan growth, and Zoetis Inc.'s strong Q4 performance and fiscal 2026 outlook.